We evaluated the efficacy of topical brimonidine in visual field preser vation and/or improvement in eyes undergoing controlled glaucoma.
Methods
Seventy eyes of patients were trained with two different visual field test strategies: The Octopus Tendency Oriented Perimetry (TOP) G1 and the Frequency Doubling Technology (FDT) 30°. Following 2–4 months of brimonidine treatment, there were significant improvements in visual field, as assessed using the TOP G1 strategy (p = 0.003). The FDT 30° test revealed no statistically significant differences.
Conclusions
These data support the results of other studies, which indicate that brimonidine may increase mean sensitivity in visual field tests. Since it is known that the control of intraocular pressure does not fully protect glaucomatous eyes from visual field loss, it is possible that the neuroprotective qualities of brimonidine may contribute to visual field preservation in glaucomatous eyes.
KimC.S., HayrehS.S., AlwardW.L.M., KwonY.H.. Rate of visual field decline in primary open-angle glaucoma.Invest Ophthalmol Vis Sci2000; 41(suppl): S89.
2.
JavittJ., GoldbergI.. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II.J Glaucoma2000; 9: 398–408.
3.
Levkovitch-VerbinH., Harris-CerrutiC., GronerY., WheelerL.A., SchwartzM., YolesE.. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection.Invest Ophthalmol Vis Sci2000; 41: 4169–74.
4.
AdelsonA., KrupinT.. Effect of patient experience on the results of automated perimetry in clinically stable glaucoma patients.Ophthalmology1988; 95: 764–7.
5.
AutzenT., WorkK.. The effect of learning and age on short-term fluctuation and mean sensitivity of automated static perimetry.Acta Ophthalmol1990; 68: 327–30.
6.
LesterM., CaprisP., PandolfoA., ZingirianM., TraversoC.E.. Learning effect, short-term fluctuation, and long-term fluctuation in frequency doubling technique.Am J Ophthalmol2000; 130: 160–4.
7.
Azuara-BlancoA., KingA.J.W., TaguriA.. Comparison of two fast strategies for visual field assessment in glaucoma: Humphrey's SITA-Fast and Octopus' TOP.Invest Ophthalmol Vis Sci2000; 41(suppl): S88.
8.
BassS.J., Abraham-CohenJ., FeldmanJ., WyattH.. Humphrey SITA vs Octopus TOP in glaucoma patients.Invest Ophthalmol Vis Sci2000; 41(suppl): S88.
9.
FujimotoN., Adachi-UsamiE.. Frequency doubling perimetry in resolved optic neuritis.Invest Ophthalmol Vis Sci2000; 41(suppl): S2558–60.
10.
TribleJ.R., SchultzR.O., RobinsonJ.C., RotheT.L.. Accuracy of glaucoma detection with frequency-doubling perimetry.Am J Ophthalmol2000; 129: 740–5.
11.
TorisC.B., GleasonM.L., CamrasC.B., YablonskiM.E.. Effects of brimonidine on aqueous humor dynamics in human eyes.Ophthalmology1995; 113: 1514–7.
12.
TorisC.B., CamrasC.B., YablonskiM.E.. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients.Am J Ophthalmol1999; 128: 8–14.
13.
KatzL.J., and the Brimonidine Study Group. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.Am J Ophthalmol1999; 127: 20–6.
14.
YolesE., WheelerL.A., SchwartzM.. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration.Invest Ophthalmol Vis Sci1999; 40: 65–73 and published erratum in Invest Ophthalmol Vis Sci 1999; 40 (Suppl): S2470.
15.
WoldeMussieE., RuizG., WijonoM., WheelerM.. Neuroprotective effect of brimonidine in chronic ocular hypertensive rats.Invest Ophthalmol Vis Sci2000; 41(suppl): S830.
16.
BurkeJ., SchwartzM.. Preclinical evaluation of brimonidine.Surv Ophthalmol1996; 41(suppl): S9–18.
17.
PengM., LiY., LuoC., LatiesA.M., WenR.. A novel mechanism regulating expression of GFAP mediated by PI3K-MAPK signaling pathway in Muller cells in response to a2-adrenergic agonists.Soc Neurosci1997; 23: 1671.
18.
LaiR.K., HassonD.W., WheelerL.A.. Neuroprotective effect of brimonidine.Invest Ophthalmol Vis Sci1997; 38(suppl): S590.
19.
WenR., ChengT., LiY., CaoW., SteinbergR.H.. Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage.J Neurosci1996; 16: 5986–92.
20.
Nacif-CoelhoC., Correa-SalesC., ChangL.L., MazeM.. Perturbation of ion channel conductance alters the hypnotic response to the alpha2-adrenergic agonist dexmedetomidine in the locus coeruleus of the rat.Anesthesiology1994; 81: 1527–34.
21.
DonelloJ.E., PadilloE.U., WebsterM.L., WheelerL.A., GilD.W.. Alpha(2)-adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia.J Pharmacol Exp Ther2001; 296: 216–23.
22.
DreyerE.B., ZurakowskiD., SchumerR.A., PodosS.M., LiptonS.A.. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma.Arch Ophthalmol1996; 114: 299–305.
23.
MastropasquaL., CiancagliniM., CarpinetoP., ZuppardiE., FalconioG., GallengaP.E.. Effects of brimonidine 0.2% on blue-yellow perimetry of glaucomatous patients.Acta Ophthalmol Scand1998; 227(suppl): S36.
24.
LachkarY., MigdalC., DhanjilS.. Effect of brimonidine tartrate on ocular hemodynamic measurements.Arch Ophthalmol1998; 116: 1591–4.
25.
CarlssonA.M., ChauhanB.C., LeeA.A., LeBlancR.P.. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension.Am J Ophthalmol2000; 129: 297–301.
26.
MelamedS., DavidR.. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II.Clin Ther2000; 22: 103–11.
27.
LeBlancR.P.. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.Ophthalmology1998; 105: 1960–7.
28.
MirzaG.E., KarakucukS., TemelE.. Comparison of the effects of 0.5% timolol maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects.J Glaucoma2000; 9: 45–50.
29.
Vainio-JylhäE., VuoriM.L.. The favorable effect of topical betaxolol and timolol on glaucomatous visual fields: a 2-year follow-up study.Graefes Arch Clin Exp Ophthalmol1999; 237: 100–4.
